Search

Displaying results 2891 - 2900 of 7452 in total
  1. Drug

    Gabapentin enacarbil

    go.drugbank.com/drugs/DB08872
    Approved

    It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

  2. Drug

    Carbon dioxide

    go.drugbank.com/drugs/DB09157
    ApprovedInvestigationalVet approved

    during bodily investigations, to inflate body cavities during surgery (such as key-hole surgery), and in solid form (dry ice) for freezing of tissue and removal of warts.

  3. Drug

    Domperidone

    go.drugbank.com/drugs/DB01184
    ApprovedInvestigationalVet approved

    A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

    Categories: Drugs for Functional Gastrointestinal Disorders
  4. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.

  5. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. … Zimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like … Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic.

  7. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020].

  8. Indication

    Lenticular opacities

    go.drugbank.com/conditions/DBCOND0010192
    Drugs: Bendazac
    Synonyms: Cataract form (observable entity)
  9. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

  10. Drug

    Enpatoran

    go.drugbank.com/drugs/DB16501
    Investigational

    Enpatoran (M5049) was under investigation in clinical trials for various conditions. … Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis

    Categories: Experimental Unapproved Treatments for COVID-19